Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05767528

Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection

Muscle-Invasive Bladder Carcinoma Clinical Trial

Official title:
Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection

Clinical Trial Summary

In this study, investigators plan to conduct the 3D in vitro culture PTC drug sensitivity testing of fresh tumor specimen which obtained by endoscopic biopsy or other methods. Through assessing the consistency between the testing results and the patients' neoadjuvant treatment outcomes, they would evaluate the accuracy of PTC drug sensitivity testing and its application value in the individualized precision medicine for muscle-invasive bladder carcinoma.

Clinical Trial Description

This is a prospective observational study. In this study, researchers propose to enroll 40 participants above 18 years of age with muscle-invasive bladder carcinoma, who are going to receive the neoadjuvant therapy before surgery. Collecting fresh tumor samples for PTC drug sensitivity testing, conducting neoadjuvant therapy for the subjects simultaneously. By combining PTC prediction results with the patients' clinical treatment process and medication feedback, researchers could estimate the accuracy of PTC drug sensitivity testing. Completion of this research would provide real-world figures to support for the clinical application for PTC drug sensitivity testing, and a method is going to be established to guide the clinical treatment regimen for patients with muscle-invasive bladder carcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05767528
Study type Observational
Source Chinese PLA General Hospital
Contact Shaoxi Niu, M.D.&Ph.D.
Phone +8613911353443
Email g4niuniu@163.com
Status Recruiting
Phase
Start date December 8, 2022
Completion date December 8, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05097404 - Clinical Utility of VI-RADS in Diagnosis of MIBC
Recruiting NCT05483868 - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer Phase 1
Not yet recruiting NCT04966130 - Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
Active, not recruiting NCT04610671 - Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC Phase 1
Recruiting NCT06341400 - RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients Phase 1/Phase 2
Recruiting NCT05203913 - Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05790850 - Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) N/A
Recruiting NCT05295992 - Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach N/A
Recruiting NCT06215976 - The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer Phase 4
Recruiting NCT05028660 - AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
Not yet recruiting NCT04909775 - Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT04876313 - An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) Phase 2
Not yet recruiting NCT04686149 - a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
Active, not recruiting NCT05630131 - ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
Recruiting NCT06170177 - Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Terminated NCT05221827 - Clinical Performance Evaluation of the C2i-Test
Recruiting NCT06257017 - Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial Phase 2
Completed NCT04598724 - Addressing Barriers to Palliative Care Use in Bladder Cancer
Recruiting NCT05975307 - Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation Phase 2
Suspended NCT04506554 - A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Phase 2